Non-Invasive Prenatal Screening (NIPS)

Labassure’s NIPT analyzes cell-free fetal DNA (cfDNA) from maternal blood.

The test provides high-sensitivity:
‍

• Common Aneuploidies:
  • Trisomy 21 (Down syndrome)
  • Trisomy 18 (Edwards syndrome)
  • Trisomy 13 (Patau syndrome)
• Sex Chromosome Aneuploidies:
  • Turner syndrome (45,X)
  • Klinefelter syndrome (47,XXY)
  • Triple X (47,XXX)
  • XYY syndrome (47,XYY)
• Expanded panels may include screening for select microdeletions and rare autosomal trisomies based on clinical request.

‍

• Sample Type: Maternal peripheral blood
• Volume Required: 10 ml
• Vial Type: Streck Cell-Free DNA BCT (specialized cfDNA tube; provided by Labassure)
• Collection Window: After 10 weeks of gestation
• Processing Time: Results typically available in 7–10 working days
• Pre-Test Counseling: Recommended, especially in high-risk pregnancies
• No fasting or special preparation required

Benefits of NIPT
‍

Safe and Non-Invasive

• NIPT only requires a maternal blood sample—eliminating the small but significant miscarriage risk associated with invasive tests like amniocentesis or CVS.
  ‍

High Accuracy:

• NIPT offers superior sensitivity and specificity (>99% for Trisomy 21) compared to traditional biochemical screening methods, significantly reducing false positives and unnecessary follow-up procedures.
  ‍

Early Detection:

• Testing can be done as early as 10 weeks, providing parents and clinicians with timely insights to support decision-making and care planning.

Informed Pregnancy Management:

• Supports personalized prenatal care, including the option for further confirmatory testing or specialist referral if needed.

‍

Advanced Genomic Technology:

• Utilizes NGS-based analysis of cfDNA to deliver accurate, reliable results—even in low fetal fraction scenarios.